PAH Clinical Trial
Official title:
Biomarkers in Pulmonary Arterial Hypertension Treated With Imatinib
The purpose of the study is to determine whether circulating molecular and cellular biomarkers are predictive of imatinib effect on pulmonary artery hypertension.
We hypothesize that bone marrow progenitor cells are mobilized into the circulation in PAH, home to the lungs and differentiate into mast cells, which promote vascular remodeling and vasoconstriction through release of renin and chymase. As a corollary to this, we hypothesize that anti cKit tyrosine kinase inhibitor (TKI), imatinib, provides clinical benefit to patients through inhibition of mast cell progenitor proliferation, mobilization and differentiation. To test this, we will determine if mast cell progenitors and mast cell biomarkers are related to imatinib clinical response. This will be an ancillary study, part of a placebo-controlled, double-blind multi center clinical trial of imatinib in pulmonary arterial hypertension. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Recruiting |
NCT04796337 -
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
|
Phase 3 | |
| Not yet recruiting |
NCT04309838 -
Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension
|
||
| Withdrawn |
NCT02149095 -
Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
|
Phase 1 | |
| Terminated |
NCT04084678 -
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
|
Phase 3 | |
| Completed |
NCT02276872 -
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
|
Phase 2 | |
| Terminated |
NCT04053543 -
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
|
Phase 2 | |
| Recruiting |
NCT03626688 -
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
|
Phase 3 | |
| Withdrawn |
NCT01320865 -
Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib
|
N/A | |
| Terminated |
NCT03449524 -
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
|
Phase 2 |